Table 1. Characteristics of patients who underwent restaging PET-CT in the work-up for potentially curative esophagectomy.
| Patients’ characteristics | N = 156 | |
|---|---|---|
| Age, median (range) | 65 (34–83) | |
| Sex, male (%) | 119 (76.3%) | |
| Tumor location | ||
| Middle thoracic (%) | 12 (7.7%) | |
| Lower thoracic (%) | 101 (64.7%) | |
| Esophagogastric junction / cardia (%) | 43 (27.6%) | |
| Tumor histology | ||
| Adenocarcinoma (%) | 126 (80.8% | |
| Squamous cell carcinoma (%) | 29 (18.6%) | |
| Other (%) | 1 (0.6%) | |
| AJCC Stage [31] | ||
| IB (%) | 5 (3.2%) | |
| IIA (%) | 7 (4.5%) | |
| IIB (%) | 38 (24.4%) | |
| IIIA (%) | 55 (35.3%) | |
| IIIB (%) | 36 (23.1%) | |
| IIIC (%) | 11 (7.1%) | |
| Unknown (%) | 4 (2.6%) | |
| Neoadjuvant therapy regimen | ||
| Radiotherapy (41.4Gy), carboplatin, paclitaxel (%) a | 139 (89.1%) | |
| Radiotherapy (41.4Gy), carboplatin, paclitaxel, panitumumab(%) b | 17 (10.9%) |
AJCC, American Joint Committee on Cance
a including 6 cases of incomplete neoadjuvant treatment due to toxicity
b treatment as part of a phase II clinical trial